Somewhat Positive Press Coverage Somewhat Unlikely to Affect Novadaq Technologies (NVDQ) Stock Price
Press coverage about Novadaq Technologies (NASDAQ:NVDQ) (TSE:NDQ) has trended somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novadaq Technologies earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.2215599137449 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Comparing Novadaq Technologies (NVDQ) & Analogic Corporation (ALOG) (americanbankingnews.com)
- Novadaq Announces Voting Results of Special Meeting of Shareholders – GlobeNewswire (press release) (globenewswire.com)
- Novadaq Technologies Inc (NASDAQ:NVDQ) Sees Large Decrease in Short Interest (campdesrecrues.com)
- Novadaq Technologies Inc. (NVDQ) stock RSI 74.49 Reading lies in an overbought Zone – Voice Of Analysts (analystsbuzz.com)
- Novadaq Technologies Inc. (NVDQ) is at $11.71 and Nobilis Health Corp. (HLTH) is worth at $1.55 per share – Stocks Gallery (stocksgallery.com)
Shares of Novadaq Technologies (NASDAQ NVDQ) traded down 0.09% during trading on Monday, reaching $11.68. 488,257 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $11.09 and a 200 day moving average price of $8.17. Novadaq Technologies has a 12-month low of $5.84 and a 12-month high of $12.74. The company’s market capitalization is $675.13 million.
NVDQ has been the subject of a number of recent research reports. Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 target price on shares of Novadaq Technologies in a report on Friday, June 2nd. Scotiabank reiterated an “outperform” rating and issued a $18.00 target price on shares of Novadaq Technologies in a report on Wednesday, April 26th. Zacks Investment Research upgraded shares of Novadaq Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, May 9th. Canaccord Genuity downgraded shares of Novadaq Technologies from a “buy” rating to a “hold” rating and set a $11.75 target price for the company. in a report on Monday, July 10th. Finally, Northland Securities reiterated a “hold” rating and issued a $11.75 target price on shares of Novadaq Technologies in a report on Monday, June 19th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the company’s stock. Novadaq Technologies presently has a consensus rating of “Hold” and a consensus price target of $11.86.
About Novadaq Technologies
NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.
Receive News & Ratings for Novadaq Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.